Humanized CAR19T2 T Cell therapy（Zhaotai Cell Bio-tech）

N/A

Report date: 2024/03/19 20:00:40

Base Information

Drug NameHumanized CAR19T2 T Cell therapy（Zhaotai Cell Bio-tech）
Drug Alias NameCD19 CAR T-cell（Zhaotai Cell Bio-tech）Humanized Anti-CD19 Chimeric Antigen Receptor-T cell（Zhaotai Cell Bio-tech）CAR19T2 T cell（Zhaotai Cell Bio-tech）
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesGuangdong Zhaotai Cell Bio-tech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGuangdong Zhaotai Cell Bio-tech Co Ltd
Active IndicationsN/A
Inactive IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A